The GOC Executive Committee together with the CPD Program Planning Committee are proud to announce that our 23rd Annual Continuing Professional Development meeting will take place in Toronto, Ontario from Thursday, April 27th to Friday, April 28th, 2023, at the Sheraton Centre Toronto Hotel.
On behalf of these two committees, I would like to invite you to attend this amazing event. Get ready for an exciting two days filled with networking, reconnections with old colleagues, new connections with new colleagues, sharing of knowledge, laughter and so much more.
On April 28th, we will have an engaging and insightful program with topics such as endometrioid ovarian cancer, vulvar melanoma, sentinel lymph nodes and many more.
We will close off the meeting on Friday night with dinner and some entertainment. Don't miss this opportunity to have a wonderful time with the GOC family.
We have negotiated room discounts and secured a limited number of group-rate hotel rooms. The group rate rooms are limited and available on a first-come, first-served basis. Book early for the best selection and price ".
A valid credit card is required to secure a group rate. Cancellations received within 72 hours of arrival date will incur 1-night room and tax cancellation charge, outside of 72 hours no charge. Complimentary Wi-Fi in all guest rooms with group rate. Be sure to add your hotel rewards number when booking to receive points for your loyalty program.
Registration is now open. Take advantage of the early bird pricing and we hope to see you in Toronto!
Sincerely,
Susie Lau, MD, MSc, FRCSC
Chair, CPD Program Planning Committee
CALENDAR PLACEHOLDER - click on "calendar placeholder" then click download for the calendar invite.
Agenda
Program learning objectives
At the end of the program, participants will be able to:
Summarize the "Top Three" practice-changing peer-reviewed published articles of the past year.
Emphasize the importance of academic medicine and understand the landscape of how to publish successfully in a journal of high impact factor.
Discuss vulvar melanoma and new treatment philosophies in both the surgical and medical management of this disease.
Summarize the most recent advances in the development of new investigational treatments relevant to gynecologic-related melanomas
Discuss what is new pathologically in the analysis of vulvar cancers and the significance of margin status and sentinel lymph nodes on frozen section.
Summarize the most recent advances in the development of new investigational treatments relevant to gynecologic cancers.
Understand the concept of homologous recombination defects (HRD), the types of tests available with their limitations, and how to apply this knowledge to practice.
Introduce the principle of using the Pembrolizumab/Lenvatinib combination in non-endometrioid cancers and review research in support of this where applicable.
Review some rarer types of ovarian cancer (endometrioid) and current treatment philosophies with an emphasis on future clinical research.
Understand the concept of Time Toxicity as it is related to cancer treatment.
Emphasize the importance of assessing for frailty in gynecologic oncology patients and the implications for surgical and medical management.
Improve the understanding of medical aid in dying (MAID) in the gynecologic oncology population and explore the roles of the supportive care team and gynecologic oncology team in the trajectory of care.
April 27, 2023
April 28, 2023
April 27, 2023
Meetings - Room: Wentworth
8:45 AM - 10:15 AM
Communications Committee Meeting
10:30 AM - 11:15 AM
Strategic Partner Check-in: GOC and GSK
11:30 AM - 1:00 PM
Board of Directors Meeting
7:15 PM - 9:00 PM
Concurrent CoP Dinner Meetings
1. CoP in QIPS - Room: Wentworth 2. CoP in Medical Cannabis - Room: Elgin 3. CoP in Immunotherapy - Room: Huron 4. CoP in Rare Diseases - Room: Kanora
Fellows Educational Course - Room: Provincial North
11:00 AM - 12:00 PM
Registration
12:00 PM - 12:05 PM
Welcome
12:05 PM - 12:55 PM
Review of the 2022 Landmark Papers
12:55 PM - 1:25 PM
Networking Break
1:25 PM - 2:15 PM
Setting up an Academic Career
2:15 PM - 2:30 PM
Closing Remarks and Open Discussion
Biology course - Room: Provincial North
3:00 PM - 3:10 PM
Welcome
3:10 PM - 3:40 PM
CRISPR-based Screening Technology for the Identification of Therapeutic Targets in Gynecologic Cancers
At the end of the session, participants will: 1. Review the molecular basis of CRISPR-based technology for gene editing. 2. Discuss how CRISPR screens are used to identify drug targets including synergistic activation mediator (SAM) screens and synthetic lethality screens. 3. Review specific examples of this technology being used for drug discovery in ovarian cancer. (E.g. PKMYT1 synthetic lethality in CCNE1 amplified ovarian as an example of the discovery pipeline taking CRISPR screens from bench to bedside. 4. Discuss current challenges in finding therapies for gynecologic cancers (resistance, recurrence, metastases) and how the CRISPR-based technology can accelerate preclinical research.
3:40 PM - 4:10 PM
Pre-clinical models for drug discovery and testing.
At the end of the session, participants will: 1. Describe some of the most recent pre-clinical models for the study of ovarian cancer. 2. Evaluate the strengths and limitations of the different model systems. 3. Recognize how these models can be used to test new therapeutic interventions. 4. Evaluate the potential of these models to serve in clinical decision making.
4:10 PM - 4:35 PM
Networking Break
4:35 PM - 5:05 PM
Preclinical Research Requirements for Clinical Trial Readiness in Gynecologic Cancers
At the end of the session, participants will: 1. Review the types of in-vitro and/or in-vivo experiments and processes required for clinical trial approval. 2. Discuss examples of how preclinical data quality can lead to success and/or failure in the conduct of Phase 1 clinical trials. 3. Review novel clinical trials designs for the evaluation of targeted therapies in the era of molecular subtypes. 4. Discuss the use of predictive biomarkers to guide clinical trial design.
5:05 PM - 5:15 PM
Wrap up
5:15 PM - 7:15 PM
Fellows Half-Day Reception and Speed Networking - Room: Provincial South
CPD Plenary - Room: Civic Ballroom
No Scheduled items for this day
April 28, 2023
Meetings - Room: Wentworth
No Scheduled items for this day
Fellows Educational Course - Room: Provincial North
No Scheduled items for this day
Biology course - Room: Provincial North
No Scheduled items for this day
CPD Plenary - Room: Civic Ballroom
7:15 AM - 8:00 AM
Registration & Breakfast
8:00 AM - 8:10 AM
Welcome
8:10 AM - 8:25 AM
Top 3 Articles of the Year, paper 1: Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles
At the end of the session, participants will:
1. Describe the findings of this retrospective study Perform a critical appraisal of the employed methodology. 2. Describe clinical characteristics, pathologic features, and mutational patterns associated with MSI-H endometrial cancer with MLH1 promotor hypermethylation. 3. Discuss the clinical implications of epigenetic MLH1 promotor hypermethylation in endometrial cancer.
8:25 AM - 8:40 AM
Top 3 Articles of the Year, paper 2: A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006)
At the end of the session, participants will:
1. Describe tumor-targeted agent biology with folate receptor in ovarian cancer cells. 2. Determine indication of pafolacianine injection, its technique of use in ovarian cancer surgery and its potential benefice on oncological outcome. 3. Assess pafolacianine injection safety for intraoperative management of ovarian cancer.
8:40 AM - 8:55 AM
Top 3 Articles of the Year, paper 3: Effectiveness of Intensive Versus Minimalist Follow-Up Regimen on Survival in Patients With Endometrial Cancer (TOTEM Study: A Randomized, Pragmatic, Parallel Group Multicenter Trial
At the end of the session, participants will:
1. Perform a critical appraisal of a pragmatic, parallel group, randomized control trial. 2. Describe the evidence for minimal versus intensive follow up regimens for surgically treated endometrial cancer.
8:55 AM - 9:00 AM
Top 3 Articles of the Year wrap up
9:00 AM - 9:45 AM
Author, Reviewer, and Editor: Lots of Lessons Learned as a Gynecologic Oncologist
At the end of the session, participants will: 1. Understand how to approach reviewing a manuscript and what editors generally look for in a review 2. Understand basic journal/publishing metrics and internal strategy for medical journals 3. Describe the future of medical publishing and ongoing challenges and concerns
At the end of this session, participants will be able to:
1. Determine the origin of endometrioid ovarian cancer. 2. Describe the molecular features and molecular subtypes of endometrioid ovarian cancers, and their associations with outcome. 3. Identify the similarities and differences with endometrioid cancers of the uterus. 4. Define the additional clinical and translational studies required.
10:45 AM - 11:15 AM
Surgical and Clinical Management of Endometrioid Ovarian Cancer
At the end of the session, participants will:
1. Recognize the clinical, pathological and molecular characteristics of endometrioid ovarian cancer (EnOC). 2. Discuss controversies surrounding lymph node dissection in EnOC staging. 3. Summarize the safety of fertility preservation in young patients with EnOC. 4. Describe uncommon clinical circumstances with concurrent primary or post partial surgical procedure
11:15 AM - 11:45 AM
Homologous Recombination Deficiency Testing (HRD) in Ovarian Cancer: Quality Care, Compassion, or Confusion?
At the end of the session, participants will: 1. Discuss predictive biomarker testing and its role in the future of targeted drug therapies for cancer. 2. Determine the biological basis of HRD testing and its role as a predictive biomarker in Ovarian Cancer. 3. Describe current assays for HRD testing 4. Describe current clinical applications and implications of HRD testing in Ovarian Cancer.
11:45 AM - 12:15 PM
Pembrolizumab + Lenvatinib for Non-Endometrioid Endometrial Cancers: what do we know?
At the end of this session, participants will be able to:
1. Counsel a patient on expected response rates for endometrioid endometrial cancers. 2. Understand the available evidence for non-endometrioid endometrial cancers. 3. Apply new knowledge to managing recurrent endometrial cancer of various histologies.
12:15 PM - 1:15 PM
Lunch
1:15 PM - 1:45 PM
Time Toxicity of Cancer Treatment
At the end of this session, participants will be able to: 1. To explore the concept of time toxicity in cancer care 2. To understand the current "value crisis" in oncology 3. To discuss potential solutions for the future
1:45 PM - 2:15 PM
Comprehensive Geriatric Assessment for Patients with Cancer: A Gynecologic Oncology Perspective
At the end of this session, participants will be able to: 1. Recognize the components of the Geriatric Oncology assessment. 2. Recognize geriatric areas to consider prior to cancer treatment or surgery. 3. Recognize the benefits of a comprehensive geriatric assessment on vulnerable patient outcomes.
2:15 PM - 2:45 PM
MAID 101 for Gynecologic Oncologists in Canada
At the end of this session, participants will be able to: 1. Assess our patients’ deaths. 2. Summarize the law concerning MAID. 3. Apply MAID protocol. 4. Measure the human experience behind MAID.
2:45 PM - 3:00 PM
Ovarian Cancer Canada – A Bold Vision for Growth & Impact
3:00 PM - 3:30 PM
Networking Break
3:30 PM - 4:00 PM
Vulvar Melanoma-Surgical Advances
At the end of this session, participants will be able to:
1. Recognize the role of surgical management including primary resection and lymph node assessment in patients with vulvar melanoma 2. Determine the role of systemic therapy 3. Apply new knowledge to treat patients with vulvar melanoma
4:00 PM - 4:30 PM
Vulvar Melanoma-Medical Advances
4:30 PM - 5:00 PM
Important pathologic factors in the assessment of vulvar squamous cell carcinoma
At the end of this session, participants will be able to:
1. Describe the main etiologic factors and associated immunohistochemical correlates 2. Recognize issues and controversies in the assessment of depth of invasion and margin status 3. Compare and contrast pathologic processing of lymphadenectomy vs. sentinel lymph node specimens
5:00 PM - 5:30 PM
What’s Radiating in GROINSV2 and Vulvar Cancer?
IK
5:30 PM - 5:35 PM
Closing remarks
5:35 PM - 6:30 PM
Unwind and recharge
6:30 PM - 12:00 AM
Conference dinner - Malaparte Toronto
Fellows Half-Day
Fellows Educational Course
The Society of Gynecologic Oncology of Canada is pleased to invite you to the third Fellows Educational Course. Two accomplished gynecologic oncologists will discuss topics relevant to fellows, residents, and early-career attendings.
During the first hour of the course, we will be reviewing five impactful articles in gynecologic oncology, published in 2022. We believe that this session will be beneficial to all fellows.
During the second hour of the session, we will focus on setting up your academic career. A successful academic gynecologic oncologist will share with us insightful tips and advice on how to successfully plan your career.
This Fellows Educational Course promises to be an amazing in-person session!
Learning objectives
At the end of this session, participants will be able to:
Discuss practice-changing research evidence.
Provide tools to gynecologic oncology fellows, residents, and early-career attendings to develop successful academic careers.
Identifying and Evaluating Novel Therapeutics: from Bench to Bedside
The objective of this symposium is to discuss current, relevant, molecular and cell biology discoveries, highlighting how these insights impact our understanding of the pathogenesis and treatment of cancer. The goal is to provide engaging and enlightening presentations geared to clinicians with a view to broadening their knowledge of the basic science of cancer as it relates to the prevention, detection, and treatment of cancer. Key historical advances that have shaped our approach to cancer are of interest.
For the 2023 symposium, we will be discussing how models can be used to better understand the molecular profile of different gynecological cancers, test drug responses, and improve patient outcomes.
Speakers
Alon Altman
Professor, Gynecologic Oncology at University of Manitoba, Cancercare Manitoba
Christopher Booth MD FRCPC
Professor of Oncology and Public Health Sciences Canada Research Chair in Population Cancer Care Director, Division of Cancer Care and Epidemiology at Queen's University and Kingston Health Sciences Centre
Melica Nourmoussavi Brodeur
Fellow, Postdoctoral Research at Memorial Sloan Kettering Cancer Center
Mark Carey
Professor, Gynecologic Oncology at University of British Columbia
Maxime Côté MD FRCSC
Fellow at Division of gynecology-oncology - CHU de Québec - Université Laval
Samuel Dubé
MD, FRCSC. Gynecologic oncologist. Associate Professor. at Division of Gynecologic Oncology, Université de Montréal, Montréal, Québec, Canada.
Rachelle Findley
Gynecologic Oncologist at Nova Scotia Cancer Centre
David Gallo
Senior Scientist II, Cancer Biology at Repare Therapeutics
Vishaal Gupta, MD, FRCSC, MPH
Locum Gynecologic Oncologist at Trillium Health Partners
Anjelica Hodgson
Gynecologic Pathologist at University Health Network
Liat Hogen
Gynecologic Oncologist at Princess Margaret Cancer Cente
Warner Huh
Chair of the Department of Obstetrics and Gynecology at UAB Medicine
Rahima Jamal
Medical Director, PARC/Unit for Innovative Therapies of CRCHUM
Gyn Oncologist at McGill University/Sir Mortimer B. Davis Jewish General Hospital
Marta Llaurado Fernandez
Program Manager & Research Associate, Obstetrics and Gynecology at The University of British Columbia
Genevieve MacAulay Vacheresse
Gynecologic Oncology Fellow at University of Ottawa
Taymaa May
Gynecologic Oncology at Princess Margaret Cancer Center
Anne-Marie Mes-Masson
Associate Scientific Director, Basic and Translational Research of CRCHUM
Le Thi Nguyen Gia
Medical specialist in Palliative Medicine, Medical specialist in Family Medicine, Clinical Teacher at the at University of Montreal
Lesley Roberts
Gynecologic Oncologist at University of Manitoba/Cancer Care Manitoba
Kimberly Stewart
Gynecologic Oncology Fellow at University of British Columbia
Danielle Vicus
Gynecologic Oncologist at Sunnybrook Health Sciences Centre - Odette Cancer Centre
Tania Vrionis
Chief Executive Officer at Ovarian Cancer Canada
Britta Weigelt
Associate Attending Molecular Geneticist, Department of Pathology and Laboratory Medicine Director, Gynecology DMT Research Laboratory at Memorial Sloan Kettering Cancer Center
Shannon Westin
Professor, Medical Director, Gynecologic Oncology Center Director, Early Drug Development and Phase I Trials of Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas, MD Anderson Cancer Center
Registration Fees
Thank you for registering. Note that the listed price does not include taxes. HST will be added at the end of your checkout as the event takes place in Toronto, ON. Early bird prices will be available until February 28th, 2023 at 11:59pm EST.
Cancellation and refund policy
All registration fees are non-refundable.
Questions regarding the event? Email us at enquiry@gyneoncology.ca.
We have negotiated room discounts and secured a limited number of group-rate hotel rooms. The group rate rooms are limited and available on a first-come, first-served basis. Book early for the best selection and price by clicking on the image above.
A valid credit card is required to secure a group rate. Cancellations received within 72 hours of arrival date will incur 1-night room and tax cancellation charge, outside of 72 hours there will be no charge. Complimentary Wi-Fi in all guest rooms with group rate. Be sure to add your hotel rewards number when booking to receive points for your loyalty program.
TRAVEL TO GOC'S CPD
Save 5% on standard fares, 10% on flex fares and higher (flights within North America)
Save 10% on standard fares and higher (International travel)
The booking is to be made to the following city: Toronto, YYZ (ON)
The travel period begins Thursday, April 20, 2023 and ends Saturday, May 06, 2023.
Do I have to be a GOC member to register for the event?
No, this GOC event is open to Non-members and GOC members.
Is the event virtual?
The CPD event is only available in an in-person format.
Does the CPD registration the Fellows half day?
No, the Fellows half day is a separate registration option.
When does the early bird pricing end?
February 28th, 2023, at 11:59pm PST.
Does the event have any social activities?
Yes, you can attend the fellows' half-day reception on April 27th or the CPD dinner on April 28th. Please remember to add these tickets to your registration when registering.
We have negotiated room discounts and secured a limited number of group-rate hotel rooms. The group rate rooms are limited and available on a first-come, first-served basis. Book early for the best selection and price. A valid credit card is required to secure a group rate. Cancellations received within 72 hours of arrival date will incur 1-night room and tax cancellation charge, outside of 72 hours there will be no charge. Complimentary Wi-Fi in all guest rooms with group rate. Be sure to add your hotel rewards number when booking to receive points for your loyalty program.
The members of GOC's CPD Program Planning Committee are healthcare experts from various fields with a focus on gynecologic oncology care and research. The primary objective of the committee is to represent the interests of the intended audience at CPD by ensuring that the educational content of the conference aligns with the overall goals of all internal and external stakeholders attending this conference. The committee is responsible for organizing and creating the conference content while also recruiting the required faculty members.
Susie Lau
Chair
Gynecologic Oncologist
McGill University/Sir Mortimer B. Davis Jewish General Hospital
Welcome to the Online Exhibition Manual for the 23rd Continuing Professional Development (CPD) Conference and Exhibition 2023, organized by The Society of Gynecologic Oncology of Canada (GOC). The event will take place from 27-28 April 2023 in Toronto, ON. We are thrilled that you have chosen to exhibit at our event.
This online manual has been designed to simplify your planning and address any concerns you may have about the exhibition. Here you can access essential details such as important deadlines, exhibitor/sponsor registration, and more.
It is critical that you review this manual carefully, as it outlines vital deadlines that your company must meet to avoid incurring any late or additional fees.
If you have any questions or require further information, please do not hesitate to contact us at enquiry@gyneoncology.ca
General event information
Our 23rd Continuing Professional Development (CPD) meeting will be held in-person at the Sheraton Centre Toronto Hotel, located in Toronto, Ontario. The event is scheduled to take place from Thursday, April 27th to Friday, April 28th, 2023.
The event features an exceptional lineup of sessions and speakers that promise to be insightful and engaging. You may access the agenda online for more information. Click here to view the agenda.
We have negotiated room discounts and secured a limited number of group-rate hotel rooms. The group rate rooms are limited and available on a first-come, first-served basis. Book early for the best selection and price by clicking on the image above. The discounted room rate will not be available after March 28th, 2023.
A valid credit card is required to secure a group rate. Cancellations received within 72 hours of arrival date will incur 1-night room and tax cancellation charge, outside of 72 hours there will be no charge. Complimentary Wi-Fi in all guest rooms with group rate. Be sure to add your hotel rewards number when booking to receive points for your loyalty program.
SAVE ON YOUR FLIGHT
Save on your flights by using our event travel codes with Air Canada or WestJet. Click here to access the travel codes.
Exhibitions are scheduled to take place on April 28th, concurrently with the main CPD event. Your exhibitor/sponsor registration will entitle you to complimentary breakfasts, coffee breaks, and lunch during the event. If your registration includes this option, you are welcome to attend the course on April 27th as well. All representatives registered under the allocated sponsorship/exhibitor registration will have access to the courses. However, any additional representatives will need to register separately for the courses.
The main plenary on April 28th will be in the Civic ballroom. The exhibit area will be accessible during the entire conference however, we ask that your table be attended specifically during the following peak times:
09:45 - 10:15 Networking Break
12:15 - 13:15 Lunch
15:00 - 15:30 Networking Break
Booth space will be allocated by the GOC on a first-come, first-served basis, with priority given to companies whose official exhibitor contracts are received earliest.
To ensure priority space allocation, companies are advised to reserve their booth space as early as possible. Priority will also be given to companies based on their level of participation at the conference and their past support of the Society. Please note that the GOC reserves the right to accept or reject any application for space, and to relocate or reassign exhibit booths at any time for the benefit of the exhibition. Below is the floor plan of the exhibition area and plenary room.
SET UP AND DISMANTLE
The booth will be set up with the items below:
Carpet
Lounge furniture
Panel branding (3 back panels) artwork dimensions: 366px width X 866px height. ACCEPTED FILE TYPES (PDF, EPS, AI, INDD) Digital files (logo, photos, finished layouts, etc.) should be saved or exported from your design application to PDF with a minimum resolution of 300 dpi at 100% or 50% OF THE FINAL DESIRED PRODUCTION SIZE. The higher the resolution provided, the better the results. If you must send AI, EPS or INDD files, be sure to include all links and fonts. Do not submit GIF, Word (doc), PowerPoint (ppt), PNG, JPEG or any file formatted for or taken from a website as they are not suited for large format printing. Artwork files that must be opened in their native* applications and exported to the required file types. ALL files should include 1/4" (6mm) bleed on all sides and crop/cut/trim marks set at the final graphic size as shown below.
Submit all panel branding by April 6th, 2023. No extension will be provided by the printer and booth builders.
*Add-ons: TV screen and literature display rack. Please email enquiry@gyneoncology.ca if you wish to add these options.
Below is a sample of the booth space. Please note that the layout might differ slightly.
The booth contractor will commence setting up the booths on April 27th at 6:00 pm EST. You are welcome to view the booth space during the set-up process. The booth set-up is estimated to take about four hours to complete for all booths. Following this, you can proceed to set up your handouts or booth materials either on the same day or the next morning as early as 6:00 am EST.
All booths will be dismantled at 6:00 pm EST on April 28th. Please ensure that you remove all your personal belongings from the booth before the specified time. The booth contractor will be responsible for dismantling all booths.
To find out about sponsorship opportunities, click here.
